288402-91-5

Upstream product

• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 
• 545-06-2 trichloroacetonitrile 
• 288402-89-1 allyl 2-azido-3-O-[(R)-3-(benzyloxy)tetradecyl]-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside 
• 137119-93-8 (R)-3-benzyloxy-1-(methanesulfonyloxy)tetradecane 
• 139623-16-8 (R)-3-benzyloxy-1-hydroxytetradecane 
• 99519-05-8 Allyl 2-amino-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside 
• 139623-13-5 (R)-1,3-dihydroxytetradecane 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 354567-18-3 (4R)-2-phenyl-4-undecyl-1,3-dioxane 
• 288402-88-0 allyl 2-azido-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside 

Downstream Products

• 354567-45-6 diphenylmethyl 2,6-anhydro-4-O-[(R)-3-(benzyloxy)tetradecyl]-3-deoxy-5-O-diphenylphosphono-3-[(R)-3-(dodecyloxy)tetradecanamido]-D-glycero-D-ido-heptonate 
• 354567-37-6 diphenylmethyl 2,6-anhydro-4-O-[(R)-3-(benzyloxy)tetradecyl]-7-O-tert-butyldimethylsilyl-3-deoxy-3-[(R)-3-(dodecyloxy)tetradecanamido]-D-glycero-D-ido-heptonate 
• 354567-32-1 diphenylmethyl 2,6-anhydro-4-O-[(R)-3-(benzyloxy)tetradecyl]-3-deoxy-3-[(R)-3-(dodecyloxy)tetradecanamido]-D-glycero-D-ido-heptonate 
• 354567-46-7 2,6-anhydro-3-deoxy-5-O-diphenylphosphono-3-[(R)-3-(dodecyloxy)tetradecanamido]-4-O-[(R)-3-hydroxytetradecyl]-D-glycero-D-ido-heptonate 
• 354567-27-4 2,6-anhydro-3-[(R)-3-(benzyloxy)tetradecyl]-3-deoxy-3-[(R)-3-(dodecyloxy)tetradecanamido]-5,7-O-isopropylidene-D-glycero-D-ido-heptononitrile 
• 288402-95-9 diphenylmethyl 2,6-anhydro-3-[(R)-3-(benzyloxy)tetradecanamido]-4-O-[(R)-3-(benzyloxy)tetradecyl]-3-deoxy-D-glycero-D-ido-heptonate 
• 288402-94-8 2,6-anhydro-3-[(R)-3-(benzyloxy)tetradecanamido]-4-O-[(R)-3-(benzyloxy)tetradecyl]-3-deoxy-5,7-O-isopropylidene-D-glycero-D-ido-heptononitrile 
• 288402-93-7 (4aR,6S,7S,8R,8aS)-7-Amino-8-((R)-3-benzyloxy-tetradecyloxy)-2,2-dimethyl-hexahydro-pyrano[3,2-d][1,3]dioxine-6-carbonitrile 

Relevant academic research and scientific papers

Ether type lipid a 1-carboxylic acid analogs

A compound of formula (I) below, which exhibits excellent macrophage activity inhibitory action, is useful for the treatment or prophylaxis of inflammatory disorders, autoimmune diseases or septicemia. In a preferred embodiment, R1 and R3

Synthesis of GLA-60 type pyran carboxylic acids with an alkyl chain instead of an ester chain as LPS-antagonists

Synthesis of GLA-60 type pyran carboxylic acid analogues with an alkyl chain instead of an ester chain and their LPS-antagonist activity toward human U937 cells are described.